Clinical Trials Logo
  1. Home
  2. Thromboembolism
  3. NCT00362492

Safety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement

Thromboembolism Clinical Trial

Official title:
9-10 Days Versus Prolonged Thromboprophylaxis in Patients Without Evidence of Ultrasound Proximal Thromboembolism After Total Knee Joint Replacement: a Randomized Controlled Trial

Clinical Trial Summary

The purpose of this study is to determine whether stopping Low Molecular Weight Heparin (LMWH) thromboprophylaxis is safe after total knee joint replacement. The investigators select patients without proximal thromboembolism assessed by bilateral venous ultrasound examination 7-10 days after surgery. the investigators hypothesis is that stopping thromboprophylaxis is equally effective than prolonging thromboprophylaxis in order to prevent post-surgery complications in this population.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00362492
Study type Interventional
Source University Hospital, Caen
Contact
Status Completed
Phase Phase 4
Start date June 2004
Completion date June 2007
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Active, not recruiting NCT05563883 - Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
Terminated NCT02475187 - Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
Recruiting NCT00982514 - Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008 N/A
Completed NCT01420809 - Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection N/A
Terminated NCT00206089 - Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events Phase 3
Completed NCT00014352 - Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer Phase 2
Completed NCT00000614 - Prevention of Recurrent Venous Thromboembolism (PREVENT) Phase 3
Active, not recruiting NCT05656963 - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Completed NCT02935751 - Apixaban Discontinuation Prior to Major Surgery
Terminated NCT02579122 - REVIparin-BRIDging-in a General Practice Setting in GErmany
Completed NCT01696760 - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology N/A
Completed NCT00986154 - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Phase 3
Terminated NCT00662688 - Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer Phase 3
Completed NCT00260988 - A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery Phase 2/Phase 3
Terminated NCT00031837 - Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer Phase 3
Completed NCT03877770 - DVT After Cardiac Procedure
Completed NCT00024297 - Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters N/A
Recruiting NCT06118957 - Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery Phase 2